Daniel LaBarbera
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Helicases | 7 | 2025 | 145 | 4.600 |
Why?
| | DNA-Binding Proteins | 10 | 2025 | 1524 | 3.920 |
Why?
| | Antineoplastic Agents | 13 | 2025 | 2195 | 1.950 |
Why?
| | Colorectal Neoplasms | 4 | 2025 | 833 | 1.720 |
Why?
| | Spheroids, Cellular | 4 | 2020 | 79 | 1.480 |
Why?
| | Neoplasms | 6 | 2025 | 2804 | 1.430 |
Why?
| | Epithelial-Mesenchymal Transition | 6 | 2025 | 219 | 1.420 |
Why?
| | Aldehyde Reductase | 7 | 2018 | 29 | 1.350 |
Why?
| | Drug Discovery | 7 | 2022 | 149 | 1.280 |
Why?
| | Cell Line, Tumor | 23 | 2025 | 3611 | 1.270 |
Why?
| | Drug Screening Assays, Antitumor | 8 | 2020 | 197 | 1.210 |
Why?
| | DNA Topoisomerases, Type II | 5 | 2019 | 46 | 1.110 |
Why?
| | Topoisomerase II Inhibitors | 3 | 2019 | 26 | 1.110 |
Why?
| | Acridines | 3 | 2014 | 9 | 1.070 |
Why?
| | Drug Synergism | 3 | 2025 | 370 | 1.070 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 839 | 1.030 |
Why?
| | Cell Survival | 6 | 2024 | 1136 | 1.020 |
Why?
| | DNA Damage | 3 | 2024 | 446 | 1.000 |
Why?
| | Breast Neoplasms | 7 | 2025 | 2318 | 0.940 |
Why?
| | Hydrolyzable Tannins | 4 | 2014 | 6 | 0.920 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 134 | 0.900 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2025 | 205 | 0.890 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2022 | 261 | 0.890 |
Why?
| | Cell Cycle Checkpoints | 1 | 2025 | 104 | 0.860 |
Why?
| | Molecular Targeted Therapy | 2 | 2025 | 431 | 0.830 |
Why?
| | TCF Transcription Factors | 2 | 2020 | 19 | 0.790 |
Why?
| | Antigens, Neoplasm | 3 | 2016 | 324 | 0.790 |
Why?
| | Plant Extracts | 2 | 2017 | 212 | 0.770 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 161 | 0.740 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2024 | 941 | 0.730 |
Why?
| | Small Molecule Libraries | 4 | 2020 | 107 | 0.680 |
Why?
| | Cell Plasticity | 1 | 2021 | 39 | 0.650 |
Why?
| | Imidazoles | 5 | 2021 | 252 | 0.650 |
Why?
| | Clonal Evolution | 1 | 2020 | 47 | 0.620 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 443 | 0.610 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 375 | 0.600 |
Why?
| | Histones | 1 | 2023 | 666 | 0.550 |
Why?
| | Naegleria fowleri | 1 | 2017 | 1 | 0.540 |
Why?
| | Larrea | 1 | 2017 | 1 | 0.540 |
Why?
| | Entamoeba histolytica | 1 | 2017 | 10 | 0.540 |
Why?
| | Antiprotozoal Agents | 1 | 2017 | 15 | 0.530 |
Why?
| | Giardia lamblia | 1 | 2017 | 23 | 0.530 |
Why?
| | Drug Design | 5 | 2022 | 173 | 0.520 |
Why?
| | Neoplastic Stem Cells | 4 | 2020 | 414 | 0.490 |
Why?
| | Apoptosis | 8 | 2024 | 2519 | 0.490 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2016 | 26 | 0.480 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 569 | 0.450 |
Why?
| | Adenosine Triphosphate | 3 | 2019 | 488 | 0.440 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 875 | 0.440 |
Why?
| | Hepatocytes | 1 | 2015 | 219 | 0.430 |
Why?
| | Porifera | 3 | 2009 | 8 | 0.430 |
Why?
| | Colonic Neoplasms | 2 | 2016 | 259 | 0.430 |
Why?
| | Amidines | 1 | 2013 | 15 | 0.410 |
Why?
| | Heterocyclic Compounds | 1 | 2013 | 23 | 0.410 |
Why?
| | beta Catenin | 1 | 2016 | 256 | 0.410 |
Why?
| | Humans | 43 | 2025 | 143560 | 0.410 |
Why?
| | Glycosides | 1 | 2013 | 42 | 0.400 |
Why?
| | Amides | 1 | 2013 | 97 | 0.400 |
Why?
| | Adenocarcinoma | 1 | 2020 | 911 | 0.390 |
Why?
| | Cell Proliferation | 8 | 2025 | 2542 | 0.390 |
Why?
| | Animals | 21 | 2025 | 38010 | 0.380 |
Why?
| | Phyllanthus emblica | 1 | 2012 | 1 | 0.370 |
Why?
| | Retinoids | 1 | 2012 | 34 | 0.370 |
Why?
| | Mice | 15 | 2024 | 18378 | 0.350 |
Why?
| | Fruit | 1 | 2012 | 147 | 0.340 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 772 | 0.340 |
Why?
| | Promoter Regions, Genetic | 7 | 2022 | 1263 | 0.320 |
Why?
| | Keratin-5 | 3 | 2017 | 48 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1487 | 0.310 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2011 | 141 | 0.310 |
Why?
| | Telomerase | 2 | 2022 | 249 | 0.310 |
Why?
| | Transcription, Genetic | 3 | 2021 | 1511 | 0.310 |
Why?
| | Alkaloids | 1 | 2009 | 28 | 0.300 |
Why?
| | Thyroid Carcinoma, Anaplastic | 2 | 2019 | 33 | 0.280 |
Why?
| | Caspases | 1 | 2009 | 246 | 0.280 |
Why?
| | Quinoxalines | 2 | 2007 | 67 | 0.280 |
Why?
| | Catalytic Domain | 2 | 2023 | 224 | 0.280 |
Why?
| | Models, Molecular | 6 | 2015 | 1622 | 0.270 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2021 | 230 | 0.270 |
Why?
| | Models, Biological | 3 | 2017 | 1831 | 0.270 |
Why?
| | Molecular Structure | 6 | 2016 | 505 | 0.260 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2006 | 135 | 0.240 |
Why?
| | Thyroid Neoplasms | 2 | 2021 | 337 | 0.240 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2025 | 25 | 0.230 |
Why?
| | Receptors, Progesterone | 3 | 2017 | 344 | 0.210 |
Why?
| | Structure-Activity Relationship | 4 | 2019 | 576 | 0.210 |
Why?
| | Oncogenes | 2 | 2022 | 119 | 0.210 |
Why?
| | Poly ADP Ribosylation | 1 | 2023 | 10 | 0.210 |
Why?
| | Fluorouracil | 1 | 2024 | 210 | 0.210 |
Why?
| | Benzimidazoles | 1 | 2005 | 193 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1827 | 0.200 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1282 | 0.200 |
Why?
| | Progesterone | 3 | 2017 | 258 | 0.200 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 54 | 0.200 |
Why?
| | Indoles | 1 | 2006 | 479 | 0.180 |
Why?
| | Integrins | 1 | 2022 | 94 | 0.180 |
Why?
| | Tripartite Motif-Containing Protein 28 | 1 | 2021 | 21 | 0.170 |
Why?
| | Female | 12 | 2025 | 77251 | 0.170 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 682 | 0.170 |
Why?
| | HEK293 Cells | 3 | 2012 | 748 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 151 | 0.160 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 16 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 183 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2020 | 83 | 0.160 |
Why?
| | Carcinogenesis | 1 | 2022 | 232 | 0.160 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 34 | 0.160 |
Why?
| | Binding, Competitive | 1 | 2019 | 194 | 0.150 |
Why?
| | Mutation | 5 | 2022 | 4053 | 0.150 |
Why?
| | Carrier Proteins | 1 | 2023 | 752 | 0.150 |
Why?
| | HIV Protease | 1 | 2019 | 4 | 0.150 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 336 | 0.150 |
Why?
| | Depsipeptides | 2 | 2011 | 15 | 0.150 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2022 | 272 | 0.150 |
Why?
| | PTEN Phosphohydrolase | 1 | 2020 | 165 | 0.150 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 37 | 0.150 |
Why?
| | Glioblastoma | 1 | 2022 | 350 | 0.150 |
Why?
| | Cell Cycle | 2 | 2014 | 648 | 0.140 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.140 |
Why?
| | Organoids | 1 | 2020 | 133 | 0.140 |
Why?
| | Nuclear Proteins | 1 | 2023 | 749 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2020 | 197 | 0.140 |
Why?
| | Drug Resistance | 1 | 2019 | 153 | 0.140 |
Why?
| | alpha-Glucosidases | 1 | 2018 | 9 | 0.140 |
Why?
| | Solanum tuberosum | 1 | 2018 | 7 | 0.140 |
Why?
| | alpha-Amylases | 1 | 2018 | 16 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 213 | 0.140 |
Why?
| | Polyphenols | 1 | 2018 | 19 | 0.140 |
Why?
| | Masoprocol | 1 | 2017 | 3 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 921 | 0.130 |
Why?
| | Naphthols | 1 | 2017 | 6 | 0.130 |
Why?
| | Viral Nonstructural Proteins | 1 | 2018 | 67 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 258 | 0.130 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2017 | 16 | 0.130 |
Why?
| | Receptors, Retinoic Acid | 1 | 2017 | 42 | 0.130 |
Why?
| | Mice, Nude | 3 | 2021 | 710 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 213 | 0.130 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1369 | 0.130 |
Why?
| | Chikungunya virus | 1 | 2018 | 87 | 0.130 |
Why?
| | Emodin | 1 | 2016 | 3 | 0.120 |
Why?
| | Receptors, Estrogen | 3 | 2017 | 425 | 0.120 |
Why?
| | Marine Toxins | 1 | 2015 | 12 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2056 | 0.120 |
Why?
| | Xanthines | 1 | 2015 | 23 | 0.120 |
Why?
| | Protein Interaction Maps | 1 | 2016 | 49 | 0.120 |
Why?
| | Biological Products | 2 | 2011 | 246 | 0.120 |
Why?
| | Tretinoin | 2 | 2017 | 124 | 0.120 |
Why?
| | Transcriptome | 1 | 2022 | 1029 | 0.120 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 140 | 0.120 |
Why?
| | Sorbitol | 2 | 2012 | 13 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 430 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4522 | 0.120 |
Why?
| | Down Syndrome | 1 | 2022 | 514 | 0.110 |
Why?
| | Progestins | 2 | 2012 | 85 | 0.110 |
Why?
| | Microglia | 2 | 2014 | 257 | 0.110 |
Why?
| | Retinal Pigments | 1 | 2014 | 6 | 0.110 |
Why?
| | Acid Phosphatase | 1 | 2014 | 14 | 0.110 |
Why?
| | Virus Replication | 1 | 2018 | 544 | 0.110 |
Why?
| | Rhodamines | 1 | 2014 | 20 | 0.110 |
Why?
| | G2 Phase | 1 | 2014 | 41 | 0.110 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2016 | 202 | 0.110 |
Why?
| | Neoplasm Transplantation | 2 | 2019 | 253 | 0.110 |
Why?
| | Lens, Crystalline | 2 | 2016 | 134 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2016 | 222 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 518 | 0.110 |
Why?
| | Quinones | 1 | 2013 | 9 | 0.100 |
Why?
| | Drug Stability | 1 | 2013 | 165 | 0.100 |
Why?
| | Endotoxins | 1 | 2014 | 213 | 0.100 |
Why?
| | Cataract | 1 | 2016 | 235 | 0.100 |
Why?
| | Retinal Diseases | 1 | 2014 | 96 | 0.100 |
Why?
| | Transcription Factors | 1 | 2021 | 1754 | 0.100 |
Why?
| | Green Fluorescent Proteins | 2 | 2012 | 404 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 1008 | 0.100 |
Why?
| | Acitretin | 1 | 2012 | 3 | 0.100 |
Why?
| | Miconazole | 1 | 2012 | 5 | 0.100 |
Why?
| | Isotretinoin | 1 | 2012 | 25 | 0.090 |
Why?
| | Hydrobromic Acid | 1 | 2012 | 1 | 0.090 |
Why?
| | Lung | 1 | 2025 | 4101 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2580 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2020 | 2852 | 0.090 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 104 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 764 | 0.090 |
Why?
| | Tissue Culture Techniques | 1 | 2012 | 82 | 0.090 |
Why?
| | Eye | 1 | 2012 | 114 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 91 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 198 | 0.090 |
Why?
| | Genes, Reporter | 1 | 2012 | 273 | 0.090 |
Why?
| | Retina | 1 | 2014 | 324 | 0.090 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 173 | 0.090 |
Why?
| | Oxazoles | 1 | 2011 | 47 | 0.080 |
Why?
| | Vimentin | 1 | 2011 | 52 | 0.080 |
Why?
| | Hyperglycemia | 1 | 2014 | 365 | 0.080 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 974 | 0.080 |
Why?
| | Software | 1 | 2015 | 687 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1064 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2012 | 510 | 0.080 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 861 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2022 | 4182 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 174 | 0.070 |
Why?
| | Macrophages | 2 | 2014 | 1506 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2014 | 1125 | 0.070 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 1091 | 0.070 |
Why?
| | Stereoisomerism | 1 | 2007 | 103 | 0.070 |
Why?
| | Hydrocarbons, Halogenated | 1 | 2007 | 5 | 0.070 |
Why?
| | Computer Simulation | 1 | 2012 | 1028 | 0.070 |
Why?
| | Heat-Shock Response | 1 | 2008 | 79 | 0.070 |
Why?
| | Beauveria | 1 | 2006 | 2 | 0.060 |
Why?
| | Mycotoxins | 1 | 2006 | 4 | 0.060 |
Why?
| | Quinolines | 1 | 2008 | 171 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 234 | 0.060 |
Why?
| | Pyrroles | 1 | 2007 | 210 | 0.060 |
Why?
| | Fungal Proteins | 1 | 2006 | 141 | 0.060 |
Why?
| | Protein Binding | 1 | 2012 | 2261 | 0.060 |
Why?
| | Solutions | 1 | 2006 | 168 | 0.060 |
Why?
| | Peptides, Cyclic | 1 | 2007 | 273 | 0.060 |
Why?
| | Quinolones | 1 | 2007 | 180 | 0.060 |
Why?
| | Catalysis | 1 | 2006 | 322 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2025 | 249 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 6043 | 0.050 |
Why?
| | Imidazolidines | 2 | 2014 | 10 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 556 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 856 | 0.050 |
Why?
| | Melanoma, Experimental | 1 | 2005 | 111 | 0.050 |
Why?
| | Models, Chemical | 1 | 2005 | 273 | 0.050 |
Why?
| | Autophagy | 1 | 2025 | 287 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1628 | 0.050 |
Why?
| | Oxidative Stress | 2 | 2022 | 1370 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2022 | 39 | 0.050 |
Why?
| | Inflammation | 1 | 2012 | 2881 | 0.040 |
Why?
| | Oximes | 1 | 2021 | 26 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 732 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2014 | 642 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 78 | 0.040 |
Why?
| | Mass Spectrometry | 2 | 2018 | 740 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2021 | 273 | 0.040 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2020 | 88 | 0.040 |
Why?
| | Fibroblasts | 1 | 2025 | 1044 | 0.040 |
Why?
| | Azacitidine | 1 | 2020 | 149 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 325 | 0.040 |
Why?
| | Depsides | 1 | 2018 | 2 | 0.040 |
Why?
| | Signal Transduction | 2 | 2025 | 5214 | 0.040 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2020 | 261 | 0.040 |
Why?
| | Salicylates | 1 | 2018 | 29 | 0.030 |
Why?
| | RNA Caps | 1 | 2018 | 33 | 0.030 |
Why?
| | Vero Cells | 1 | 2018 | 87 | 0.030 |
Why?
| | Cell Line | 2 | 2018 | 2897 | 0.030 |
Why?
| | Piperazines | 1 | 2021 | 393 | 0.030 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 32 | 0.030 |
Why?
| | Proteolysis | 1 | 2019 | 175 | 0.030 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 50 | 0.030 |
Why?
| | Cricetinae | 1 | 2018 | 300 | 0.030 |
Why?
| | Lactones | 1 | 2018 | 58 | 0.030 |
Why?
| | Fluorescence | 1 | 2018 | 162 | 0.030 |
Why?
| | Anthocyanins | 1 | 2018 | 35 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 312 | 0.030 |
Why?
| | Stem Cells | 1 | 2021 | 619 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 492 | 0.030 |
Why?
| | Aldo-Keto Reductases | 1 | 2016 | 1 | 0.030 |
Why?
| | Colchicine | 1 | 2015 | 22 | 0.030 |
Why?
| | Tubulin Modulators | 1 | 2015 | 11 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2019 | 474 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2018 | 453 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 330 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 117 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 474 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 74 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 146 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 963 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 2020 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2009 | 11365 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1416 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2014 | 138 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 23 | 0.020 |
Why?
| | Computational Biology | 1 | 2018 | 677 | 0.020 |
Why?
| | MCF-7 Cells | 1 | 2012 | 130 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2017 | 558 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2014 | 210 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 273 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1223 | 0.020 |
Why?
| | Uveitis | 1 | 2012 | 148 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1314 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2014 | 1272 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2194 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1813 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 973 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4152 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 1042 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1192 | 0.020 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2008 | 47 | 0.020 |
Why?
| | Toxicity Tests, Acute | 1 | 2007 | 8 | 0.020 |
Why?
| | Marine Biology | 1 | 2007 | 4 | 0.020 |
Why?
| | Fiji | 1 | 2007 | 2 | 0.020 |
Why?
| | Antibiotics, Antitubercular | 1 | 2006 | 35 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2006 | 92 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 2097 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2008 | 623 | 0.010 |
Why?
| | Binding Sites | 1 | 2008 | 1325 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2007 | 347 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 332 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 511 | 0.010 |
Why?
| | Aged | 1 | 2019 | 25322 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 35342 | 0.010 |
Why?
| | Male | 1 | 2012 | 71500 | 0.000 |
Why?
|
|
LaBarbera's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|